Shanghai site is WuXi AppTec's headquarter, including chemistry, biology, and clinical service, providing one-stop service include chemistry, biology, testing, and formulation service for your peptide projects.
The peptide drug discovery synthesis team in Shanghai was established in 2009, covering all types of peptide related services including synthesis-purification-analysis of peptide/ peptide-small molecule conjugate/peptide-drug conjugate products, with both FFS and FTE resources.
We have a dedicated formulation development team for oral and injectable peptide drug development and manufacturing with on site analytical and QA support.
288 Fute Zhong Road Waigaoqiao Free Trade
Zone Shanghai 200131, China
Wuhan site has started operation since 2012 and provides state-of-the-art peptide drug discovery and research services with FTE and FFS resourses.
Our team is highly experienced with peptide and peptide-small molecule conjugate synthesis, serving 100+ customers worldwide with 10,000+ products every year. In addition, we are capable to support peptide non-GMP production up to kg scale.
666 Gaoxin Road East Lake High-tech Development Zone
Wuhan, 430075, China
Changzhou site is a 39 acre/157,827 m² fully integrated R&D and cGMP manufacturing campus providing a unique one-site solution for APIs and advanced intermediates, including small molecule, HPAPI, oligonucleotide, peptide and complex chemical conjugate, through preclinical and clinical development to global commercial launch. By 2025, the site will be expanded to 75 acre/303,514 m2 for 15 plants, 2 R&D centers, 400+ reactors and 1300+ scientists.
Currently with 350+ scientists dedicated to peptide CMC, the site has built strong chemistry capability of process R&D for synthesis of peptide, ligand and linker as well as various of peptide-based conjugates.
The site has also built peptide manufacturing capacity that includes 9 lines with reactors up to 1,000 L for solid phase peptide synthesis. By 2022, the site will add 4 more additional lines including two 1,000L reactors.
Changzhou site offers peptide API process R&D, manufacturing, analytical and quality control.
589 North Yulong Road XinBei District, Changzhou, 213127, China
With a total area of 170 acres, the Taixing site is designed to support global partners with integrated API process R&D and manufacturing from preclinical to commercial stages. The first phase of the project, with an area of about 53 acres, is expected to be fully operational in 2025, with an annual capacity of more than 100 metric tons of drug substance.
The first phase of the project also includes industry-leading new molecular modality platforms from laboratory to commercial scale, such as high potency APIs, oligonucleotides and peptides.
Taixing Economic Development Zone, Jiangsu China
The Wuxi city site is an integrated drug product R&D and manufacturing campus, including one R&D center and two oral solid commercial-scale plants. The R&D center with an area of 2.8 acres to house more than 500 scientists, includes oral dosage platform, sterile injectable platform as well as analytical testing platform. The two oral solid commercial-scale plants provide manufacturing, packaging, and labeling services. The newly opened R&D center includes oral, injectable and analytical platforms.
The parenteral formulation platform at our Wuxi city site is designed for vials, cartridge and pre-filled syringes with state-of-the-art equipment.
8 Xinrui Road, Xin Wu District, Wuxi, Jiangsu, 214028, China
Chengdu site has an experienced team to provide all types of custom chemistry synthesis, plus one dedicated team to provide custom synthesis for unnatural amino acids and other peptide related building blocks. The team has built a comprehensive library with 2,500+ unnatural amino acids as catalog products.
No.388 Haifa Road, Chengdu Cross-Strait Science & Technology Industrial Development Park, Wenjiang District
Chengdu, 611138, China